Editas Medicine, Inc. (EDIT) Social Stream
Editas Medicine Inc (EDIT) Price Targets From Analysts
Use the tables below to see what analysts covering Editas Medicine Inc think about its future price and what recommendations they have for investors and traders.
| Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|
| 12 | $81 | $22 | $50.75 | $38.69 | 31.17% |
The Trend in the Analyst Price Target
EDIT's average price target has moved down $4.08 over the prior 27 weeks.
Over the past 16 months, EDIT's average upside potential has been -0.57%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-09-09 | 12 | 81 | 22 | 50.75 | 64.45 | -21.26% |
| 2021-09-04 | 12 | 81 | 22 | 50.75 | 68.25 | -25.64% |
| 2021-08-28 | 12 | 81 | 23 | 50.83 | 65.53 | -22.43% |
| 2021-08-09 | 12 | 81 | 23 | 47.92 | 58.06 | -17.46% |
| 2021-08-07 | 12 | 81 | 23 | 47.92 | 55.59 | -13.8% |
| 2021-08-05 | 11 | 81 | 20 | 44.82 | 54.51 | -17.78% |
| 2021-08-01 | 11 | 81 | 20 | 44.64 | 41.86 | 6.64% |
| 2021-07-24 | 11 | 81 | 20 | 44.64 | 40.84 | 9.3% |
| 2021-07-17 | 11 | 81 | 20 | 44.64 | 42.39 | 5.31% |
| 2021-07-10 | 11 | 81 | 20 | 44.64 | 48.57 | -8.09% |
| 2021-07-03 | 11 | 81 | 20 | 44.64 | 54.90 | -18.69% |
| 2021-06-24 | 11 | 81 | 20 | 44.64 | 40.87 | 9.22% |
| 2021-06-13 | 11 | 81 | 20 | 44.64 | 37.42 | 19.29% |
| 2021-06-05 | 10 | 81 | 20 | 44.70 | 33.67 | 32.76% |
| 2021-05-03 | 8 | 81 | 20 | 49.38 | 35.59 | 38.75% |
| 2021-04-25 | 8 | 81 | 20 | 49.38 | 36.91 | 33.78% |
| 2021-04-17 | 8 | 81 | 20 | 49.38 | 34.67 | 42.43% |
| 2021-04-10 | 7 | 81 | 30 | 53.57 | 39.46 | 35.76% |
| 2021-04-03 | 7 | 81 | 30 | 53.57 | 42.83 | 25.08% |
| 2021-03-20 | 6 | 81 | 30 | 52.83 | 45.00 | 17.4% |
| 2021-03-13 | 6 | 81 | 30 | 52.83 | 46.28 | 14.15% |
| 2021-03-01 | 6 | 86 | 30 | 54.83 | 46.89 | 16.93% |
| 2021-02-27 | 6 | 86 | 30 | 54.83 | 43.86 | 25.01% |
| 2021-02-20 | 6 | 86 | 30 | 54.83 | 56.49 | -2.94% |
| 2021-02-13 | 6 | 86 | 30 | 54.83 | 57.94 | -5.37% |
| 2021-02-06 | 6 | 86 | 30 | 51.17 | 64.06 | -20.12% |
| 2021-01-30 | 7 | 86 | 30 | 48.71 | 61.35 | -20.6% |
| 2021-01-23 | 8 | 86 | 14 | 44.38 | 65.76 | -32.51% |
| 2021-01-16 | 8 | 86 | 14 | 46.75 | 76.14 | -38.6% |
| 2021-01-06 | 9 | 69 | 14 | 46.33 | 80.54 | -42.48% |
| 2020-12-18 | 9 | 69 | 14 | 46.33 | 64.41 | -28.07% |
| 2020-12-10 | 9 | 60 | 14 | 38.00 | 66.84 | -43.15% |
| 2020-12-07 | 9 | 60 | 14 | 38.00 | 39.05 | -2.69% |
| 2020-11-11 | 9 | 60 | 14 | 38.00 | 29.10 | 30.58% |
| 2020-10-21 | 8 | 65 | 28 | 41.75 | NA | NA% |
| 2020-08-21 | 7 | 65 | 28 | 43.00 | NA | NA% |
| 2020-08-07 | 8 | 65 | 28 | 41.88 | NA | NA% |
| 2020-07-25 | 8 | 55 | 27 | 38.88 | NA | NA% |
| 2020-07-04 | 8 | 55 | 27 | 38.88 | NA | NA% |
| 2020-06-16 | 8 | 55 | 27 | 38.88 | NA | NA% |
| 2020-06-16 | 9 | 55 | 27 | 38.22 | NA | NA% |
| 2020-05-11 | 8 | 55 | 27 | 37.38 | NA | NA% |
EDIT Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.79 | 2 | 6 | 6 | 0 | 0 | 17 |
The Trend in the Broker Recommendations
EDIT's average broker recommendation rating worsened by 0.37 over the prior 17 months.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- The variance in analysts' estimates of EDIT is lower than 2.97% of all US stocks.
- The number of analysts covering the stock of EDIT is greater than 90.74% of Pharmaceutical Products stocks.
- EDIT has a higher upside potential (average analyst target price relative to current price) than 20.9% of Pharmaceutical Products stocks.
- EDIT has a higher average analyst price target than 78.82% of Pharmaceutical Products stocks.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to Editas Medicine Inc are VTRS, PTCT and FOLD.
What is the outlook for EDIT? Use POWR Ratings for clearer insight into price direction.